Current Trends and Challenges in Clinical Trials for Wet Age-Related Macular Degeneration: A Review
Abstract
Background: Wet Age-Related Macular Degeneration (wAMD) is a major contributor to severe vision impairment among older adults. Although anti-VEGF therapies are available, the condition continues to pose a considerable public health issue because of challenges related to effectiveness, recurrence, and the burden of treatment.
Objectives: This review seeks to examine the latest trends, recent developments, and ongoing challenges in clinical trials for wAMD. Additionally, it assesses the impact of innovative therapeutic approaches and regulatory obstacles on the results of clinical trials.
Methodology: An extensive literature search was conducted using databases such as PubMed, Scopus, and ClinicalTrials.gov. Relevant clinical trials, systematic reviews, and regulatory guidelines from the last decade were analyzed to assess emerging trends, key barriers, and future directions in wAMD clinical research.
Results: The analysis revealed a trend towards personalized medicine, gene and cell therapies, and continuous drug delivery systems in wAMD clinical trials. Nevertheless, significant obstacles remain, such as difficulties in patient recruitment, elevated trial expenses, absence of predictive biomarkers, and the intricacies involved in assessing long-term efficacy. Additionally, variations in regulations and ethical issues hinder the seamless advancement of trials.
Conclusion: Despite advancements in clinical research for wAMD through innovative therapies and enhanced designs, it is vital to address current challenges to effectively translate promising treatments into successful real-world applications. Cooperative initiatives among researchers, clinicians, regulatory agencies, and the industry are critical for refining trial frameworks and improving patient outcomes.
Keywords: Clinical trials; management; degeneration; treatment; current status; macular
Keywords:
Clinical trials, management, degeneration, treatment, current status, macularDOI
https://doi.org/10.22270/jddt.v15i7.7283References
1. Fleckenstein M, Keenan TD, Guymer RH, Chakravarthy U, Schmitz-Valckenberg S, Klaver CC, Wong WT, Chew EY. Age-related macular degeneration. Nature reviews Disease primers. 2021 May 6;7(1):31. https://doi.org/10.1038/s41572-021-00265-2 PMid:33958600
2. Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U. Age-related macular degeneration: a review. Jama. 2024 Jan 9;331(2):147-57. https://doi.org/10.1001/jama.2023.26074 PMid:38193957
3. Thomas CJ, Mirza RG, Gill MK. Age-related macular degeneration. Medical Clinics of North America. 2021 May 1;105(3):473-91. https://doi.org/10.1016/j.mcna.2021.01.003 PMid:33926642
4. Rein DB, Wittenborn JS, Burke-Conte Z, Gulia R, Robalik T, Ehrlich JR, Lundeen EA, Flaxman AD. Prevalence of age-related macular degeneration in the US in 2019. JAMA ophthalmology. 2022 Dec 1;140(12):1202-8. https://doi.org/10.1001/jamaophthalmol.2022.4401 PMid:36326752 PMCid:PMC9634594
5. Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, Ying GS. Age-related macular degeneration preferred practice pattern®. Ophthalmology. 2020 Jan 1;127(1):P1-65. https://doi.org/10.1016/j.ophtha.2019.09.024 PMid:31757502
6. Guymer RH, Campbell TG. Age-related macular degeneration. The Lancet. 2023 Apr 29;401(10386):1459-72. https://doi.org/10.1016/S0140-6736(22)02609-5 PMid:36996856
7. Vyawahare H, Shinde P. Age-related macular degeneration: epidemiology, pathophysiology, diagnosis, and treatment. Cureus. 2022 Sep 26;14(9). https://doi.org/10.7759/cureus.29583 PMid:36312607 PMCid:PMC9595233
8. Keenan TD, Cukras CA, Chew EY. Age-related macular degeneration: epidemiology and clinical aspects. Age-related Macular Degeneration: From Clinic to Genes and Back to Patient Management. 2021:1-31. https://doi.org/10.1007/978-3-030-66014-7_1 PMid:33847996
9. Deng Y, Qiao L, Du M, Qu C, Wan L, Li J, Huang L. Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes & diseases. 2022 Jan 1;9(1):62-79. https://doi.org/10.1016/j.gendis.2021.02.009 PMid:35005108 PMCid:PMC8720701
10. Pal R, Pandey P, Chawra HS, Singh RP. Niosomal as Potential Vesicular Drug Nano-carriers for the Treatment of Tuberculosis (TB). Nanoscience & Nanotechnology-Asia. 2025 Feb;15(1):E22106812323829. https://doi.org/10.2174/0122106812323829240919050438
11. Schultz NM, Bhardwaj S, Barclay C, Gaspar L, Schwartz J. Global burden of dry age-related macular degeneration: a targeted literature review. Clinical therapeutics. 2021 Oct 1;43(10):1792-818. https://doi.org/10.1016/j.clinthera.2021.08.011 PMid:34548176
12. Mousavi E, Kafieh R, Rabbani H. Classification of dry age‐related macular degeneration and diabetic macular oedema from optical coherence tomography images using dictionary learning. IET Image Processing. 2020 Jun;14(8):1571-9. https://doi.org/10.1049/iet-ipr.2018.6186
13. Abd El-Khalek AA, Balaha HM, Alghamdi NS, Ghazal M, Khalil AT, Abo-Elsoud ME, El-Baz A. A concentrated machine learning-based classification system for age-related macular degeneration (AMD) diagnosis using fundus images. Scientific Reports. 2024 Jan 29;14(1):2434. https://doi.org/10.1038/s41598-024-52131-2 PMid:38287062 PMCid:PMC10825213
14. Miller JW, D'Anieri LL, Husain D, Miller JB, Vavvas DG. Age-related macular degeneration (AMD): a view to the future. Journal of Clinical Medicine. 2021 Mar 8;10(5):1124. https://doi.org/10.3390/jcm10051124 PMid:33800285 PMCid:PMC7962647
15. Lad EM, Chakravarthy U. The issue of end point discordance in dry age-related macular degeneration: how might clinical trials demonstrate a functional benefit?. Ophthalmology. 2023 Sep 1;130(9):890-2. https://doi.org/10.1016/j.ophtha.2023.05.020 PMid:37278678
16. de Guimaraes TA, Georgiou M, Bainbridge JW, Michaelides M. Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions. British Journal of Ophthalmology. 2021 Feb 1;105(2):151-7. https://doi.org/10.1136/bjophthalmol-2020-316195 PMid:32269060 PMCid:PMC7848059
17. Christen WG, Cook NR, Manson JE, Buring JE, Chasman DI, Lee IM, Bubes V, Li C, Haubourg M, Schaumberg DA, VITAL Research Group. Effect of vitamin D and ω-3 fatty acid supplementation on risk of age-related macular degeneration: an ancillary study of the VITAL randomized clinical trial. JAMA ophthalmology. 2020 Dec 1;138(12):1280-9. https://doi.org/10.1001/jamaophthalmol.2020.4409 PMid:33119047 PMCid:PMC7596682
18. Nguyen QD, Das A, Do DV, Dugel PU, Gomes A, Holz FG, Koh A, Pan CK, Sepah YJ, Patel N, MacLeod H. Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration. Ophthalmology. 2020 Jul 1;127(7):963-76. https://doi.org/10.1016/j.ophtha.2019.12.031 PMid:32107066
19. Kniggendorf V, Dreyfuss JL, Regatieri CV. Age-related macular degeneration: a review of current therapies and new treatments. Arquivos brasileiros de oftalmologia. 2020 Aug 7;83:552-61. https://doi.org/10.5935/0004-2749.20200082 PMid:32785436
20. Stahl A. The diagnosis and treatment of age-related macular degeneration. Deutsches Ärzteblatt International. 2020 Jul 20;117(29-30):513. https://doi.org/10.3238/arztebl.2020.0513 PMid:33087239 PMCid:PMC7588619
21. Pal R, Pandey P, Chawra HS, Khan Z. Nano Drug Delivery Carriers (Nanocarriers): A Promising Targeted Strategy in Tuberculosis and Pain Treatment. Pharmaceutical Nanotechnology. 2025 Mar 7. https://doi.org/10.2174/0122117385367493250224103839 PMid:40059418
22. Stahl A. The diagnosis and treatment of age-related macular degeneration. Deutsches Ärzteblatt International. 2020 Jul 20;117(29-30):513. https://doi.org/10.3238/arztebl.2020.0513 PMid:33087239 PMCid:PMC7588619
23. Vyawahare H, Shinde P. Age-related macular degeneration: epidemiology, pathophysiology, diagnosis, and treatment. Cureus. 2022 Sep 26;14(9). https://doi.org/10.7759/cureus.29583 PMid:36312607 PMCid:PMC9595233
24. Flores R, Carneiro Â, Vieira M, Tenreiro S, Seabra MC. Age-related macular degeneration: pathophysiology, management, and future perspectives. Ophthalmologica. 2021 Jun 15;244(6):495-511. https://doi.org/10.1159/000517520 PMid:34130290
25. Deng Y, Qiao L, Du M, Qu C, Wan L, Li J, Huang L. Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes & diseases. 2022 Jan 1;9(1):62-79. https://doi.org/10.1016/j.gendis.2021.02.009 PMid:35005108 PMCid:PMC8720701
26. Blasiak J. Senescence in the pathogenesis of age-related macular degeneration. Cellular and Molecular Life Sciences. 2020 Mar;77:789-805. https://doi.org/10.1007/s00018-019-03420-x PMid:31897543 PMCid:PMC11105088
27. Apte RS. Age-related macular degeneration. New England Journal of Medicine. 2021 Aug 5;385(6):539-47. https://doi.org/10.1056/NEJMcp2102061 PMid:34347954 PMCid:PMC9369215
28. Thomas CJ, Mirza RG, Gill MK. Age-related macular degeneration. Medical Clinics of North America. 2021 May 1;105(3):473-91. https://doi.org/10.1016/j.mcna.2021.01.003 PMid:33926642
29. Tisi A, Feligioni M, Passacantando M, Ciancaglini M, Maccarone R. The impact of oxidative stress on blood-retinal barrier physiology in age-related macular degeneration. Cells. 2021 Jan 4;10(1):64. https://doi.org/10.3390/cells10010064 PMid:33406612 PMCid:PMC7823525
30. Csaky K, Curcio CA, Mullins RF, Rosenfeld PJ, Fujimoto J, Rohrer B, Ribeiro R, Malek G, Waheed N, Guymer R, Hageman GS. New approaches to the treatment of Age-Related Macular Degeneration (AMD). Experimental eye research. 2022 Aug 1;221:109134. https://doi.org/10.1016/j.exer.2022.109134 PMid:35654115
31. Fabre M, Mateo L, Lamaa D, Baillif S, Pagès G, Demange L, Ronco C, Benhida R. Recent advances in age-related macular degeneration therapies. Molecules. 2022 Aug 10;27(16):5089. https://doi.org/10.3390/molecules27165089 PMid:36014339 PMCid:PMC9414333
32. Ricci F, Bandello F, Navarra P, Staurenghi G, Stumpp M, Zarbin M. Neovascular age-related macular degeneration: therapeutic management and new-upcoming approaches. International journal of molecular sciences. 2020 Nov 3;21(21):8242. https://doi.org/10.3390/ijms21218242 PMid:33153227 PMCid:PMC7662479
33. Pannu S, Pal R, Verma I. Exploring the Therapeutic Potential of Nanocarrier-Mediated Drug Delivery in Rheumatoid Arthritis (RA) Treatment. Current rheumatology reviews.
34. Veritti D, Sarao V, Gorni G, Lanzetta P. Anti-VEGF drugs dynamics: relevance for clinical practice. Pharmaceutics. 2022 Jan 23;14(2):265. https://doi.org/10.3390/pharmaceutics14020265 PMid:35213999 PMCid:PMC8877911
35. Bontzos G, Bagheri S, Ioanidi L, Kim I, Datseris I, Gragoudas E, Kabanarou S, Miller J, Tsilimbaris M, Vavvas DG. Nonresponders to ranibizumab anti-VEGF treatment are actually short-term responders: a prospective spectral-domain OCT study. Ophthalmology Retina. 2020 Dec 1;4(12):1138-45. https://doi.org/10.1016/j.oret.2019.11.004 PMid:31937473 PMCid:PMC7416963
36. Hong HK, Park YJ, Kim DK, Ryoo NK, Ko YJ, Park KH, Kim HM, Woo SJ. Preclinical efficacy and safety of VEGF-grab, a novel anti-VEGF drug, and its comparison to aflibercept. Investigative Ophthalmology & Visual Science. 2020 Nov 2;61(13):22-. https://doi.org/10.1167/iovs.61.13.22 PMid:33196778 PMCid:PMC7671872
37. Gupta U, Kosey S, Pal R. Advancements in Nanotechnology-Based Targeted Drug Delivery Systems for Glioblastoma Chemotherapy: A Comprehensive Review. Journal of Drug Delivery Science and Technology. 2025 Jun 13:107181. https://doi.org/10.1016/j.jddst.2025.107181
38. Tadayoni R, Sararols L, Weissgerber G, Verma R, Clemens A, Holz FG. Brolucizumab: a newly developed anti-VEGF molecule for the treatment of neovascular age-related macular degeneration. Ophthalmologica. 2021 May 5;244(2):93-101. https://doi.org/10.1159/000513048 PMid:33197916
39. Harada Y, Rao VK, Arya K, Kuntz NL, DiDonato CJ, Napchan‐Pomerantz G, Agarwal A, Stefans V, Katsuno M, Veerapandiyan A. Combination molecular therapies for type 1 spinal muscular atrophy. Muscle & nerve. 2020 Oct;62(4):550-4. https://doi.org/10.1002/mus.27034 PMid:32710634
40. Buttgereit F. Views on glucocorticoid therapy in rheumatology: the age of convergence. Nature Reviews Rheumatology. 2020 Apr;16(4):239-46. https://doi.org/10.1038/s41584-020-0370-z PMid:32076129
41. Colucciello M. Steroid/AntiVascular Endothelial Growth Factor Combination Therapy for Neovascular Age-Related Macular Degeneration. Journal of Ocular Pharmacology & Therapeutics. 2024 Apr 1;40(3). https://doi.org/10.1089/jop.2024.0013 PMid:38451532
42. Zhang W, Liu Y, Sang A. Efficacy and effectiveness of anti-VEGF or steroids monotherapy versus combination treatment for macular edema secondary to retinal vein occlusion: a systematic review and meta-analysis. BMC ophthalmology. 2022 Dec 6;22(1):472. https://doi.org/10.1186/s12886-022-02682-7 PMid:36474156 PMCid:PMC9727869
43. Pal, Rahul & Kumar, Dinesh. (2025). Solid Lipid Nanoparticles (SLNPs): A State-of-the-Art Formulation Strategy and their Applications against Tuberculosis (TB) and Analgesic Effects. Nanoscience and Nanotechnology - Asia. 10.2174/0122106812379362250602075954.
44. Csaky K, Curcio CA, Mullins RF, Rosenfeld PJ, Fujimoto J, Rohrer B, Ribeiro R, Malek G, Waheed N, Guymer R, Hageman GS. New approaches to the treatment of Age-Related Macular Degeneration (AMD). Experimental eye research. 2022 Aug 1;221:109134. https://doi.org/10.1016/j.exer.2022.109134 PMid:35654115
45. Sarkar A, Sodha SJ, Junnuthula V, Kolimi P, Dyawanapelly S. Novel and investigational therapies for wet and dry age-related macular degeneration. Drug discovery today. 2022 Aug 1;27(8):2322-32. https://doi.org/10.1016/j.drudis.2022.04.013 PMid:35460893
46. Blasiak J, Pawlowska E, Ciupińska J, Derwich M, Szczepanska J, Kaarniranta K. A new generation of gene therapies as the future of wet AMD treatment. International Journal of Molecular Sciences. 2024 Feb 17;25(4):2386. https://doi.org/10.3390/ijms25042386 PMid:38397064 PMCid:PMC10888617
47. Schultz NM, Bhardwaj S, Barclay C, Gaspar L, Schwartz J. Global burden of dry age-related macular degeneration: a targeted literature review. Clinical therapeutics. 2021 Oct 1;43(10):1792-818. https://doi.org/10.1016/j.clinthera.2021.08.011 PMid:34548176
48. de Guimaraes TA, Georgiou M, Bainbridge JW, Michaelides M. Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions. British Journal of Ophthalmology. 2021 Feb 1;105(2):151-7. https://doi.org/10.1136/bjophthalmol-2020-316195 PMid:32269060 PMCid:PMC7848059
49. Wang Y, Tang Z, Gu P. Stem/progenitor cell-based transplantation for retinal degeneration: a review of clinical trials. Cell Death & Disease. 2020 Sep 23;11(9):793. https://doi.org/10.1038/s41419-020-02955-3 PMid:32968042 PMCid:PMC7511341
50. Khan M, Aziz AA, Shafi NA, Abbas T, Khanani AM. Targeting angiopoietin in retinal vascular diseases: a literature review and summary of clinical trials involving faricimab. Cells. 2020 Aug 10;9(8):1869. https://doi.org/10.3390/cells9081869 PMid:32785136 PMCid:PMC7464130
51. Wang Y, Tang Z, Gu P. Stem/progenitor cell-based transplantation for retinal degeneration: a review of clinical trials. Cell Death & Disease. 2020 Sep 23;11(9):793. https://doi.org/10.1038/s41419-020-02955-3 PMid:32968042 PMCid:PMC7511341
52. Ammar MJ, Hsu J, Chiang A, Ho AC, Regillo CD. Age-related macular degeneration therapy: a review. Current opinion in ophthalmology. 2020 May 1;31(3):215-21. https://doi.org/10.1097/ICU.0000000000000657 PMid:32205470
53. Nicolò M, Ferro Desideri L, Vagge A, Traverso CE. Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert opinion on investigational drugs. 2021 Mar 4;30(3):193-200. https://doi.org/10.1080/13543784.2021.1879791 PMid:33471572
54. Khan H, Aziz AA, Sulahria H, Khan H, Ahmed A, Choudhry N, Narayanan R, Danzig C, Khanani AM. Emerging treatment options for geographic atrophy (GA) secondary to age-related macular degeneration. Clinical Ophthalmology. 2023 Dec 31:321-7. https://doi.org/10.2147/OPTH.S367089 PMid:36741078 PMCid:PMC9892637
55. Khanani AM, Guymer RH, Basu K, Boston H, Heier JS, Korobelnik JF, Kotecha A, Lin H, Silverman D, Swaminathan B, Willis JR. TENAYA and LUCERNE: rationale and design for the phase 3 clinical trials of faricimab for neovascular age-related macular degeneration. Ophthalmology Science. 2021 Dec 1;1(4):100076. https://doi.org/10.1016/j.xops.2021.100076 PMid:36246941 PMCid:PMC9559073
56. Csaky KG, Miller JM, Martin DF, Johnson MW. Drug approval for the treatment of geographic atrophy: how we got here and where we need to go. American journal of ophthalmology. 2024 Jul 1;263:231-9. https://doi.org/10.1016/j.ajo.2024.02.021 PMid:38387826 PMCid:PMC11162935
57. Shirley M. Faricimab: first approval. Drugs. 2022 May;82(7):825-30. https://doi.org/10.1007/s40265-022-01713-3 PMid:35474059
58. Jaffe GJ, Westby K, Csaky KG, Monés J, Pearlman JA, Patel SS, Joondeph BC, Randolph J, Masonson H, Rezaei KA. C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial. Ophthalmology. 2021 Apr 1;128(4):576-86. https://doi.org/10.1016/j.ophtha.2020.08.027 PMid:32882310
59. Nagendran M, Chen Y, Lovejoy CA, Gordon AC, Komorowski M, Harvey H, Topol EJ, Ioannidis JP, Collins GS, Maruthappu M. Artificial intelligence versus clinicians: systematic review of design, reporting standards, and claims of deep learning studies. bmj. 2020 Mar 25;368. https://doi.org/10.1136/bmj.m689 PMid:32213531 PMCid:PMC7190037
60. Pal R, Pandey P, Nogai L, Anand A, Suthar P, SahdevKeskar M, Kumar V. The future perspectives and novel approach on gastro retentive drug delivery system (GRDDS) with currrent state. Journal of Population Therapeutics and Clinical Pharmacology. 2023 Sep 19;30(17):594-613. https://doi.org/10.53555/jptcp.v30i17.2852
61. Blasiak J, Pawlowska E, Ciupińska J, Derwich M, Szczepanska J, Kaarniranta K. A new generation of gene therapies as the future of wet AMD treatment. International Journal of Molecular Sciences. 2024 Feb 17;25(4):2386. https://doi.org/10.3390/ijms25042386 PMid:38397064 PMCid:PMC10888617
62. Papadopoulos Z. Recent developments in the treatment of wet age-related macular degeneration. Current medical science. 2020 Oct;40(5):851-7. https://doi.org/10.1007/s11596-020-2253-6 PMid:32980899
63. Sarkar A, Sodha SJ, Junnuthula V, Kolimi P, Dyawanapelly S. Novel and investigational therapies for wet and dry age-related macular degeneration. Drug discovery today. 2022 Aug 1;27(8):2322-32. https://doi.org/10.1016/j.drudis.2022.04.013 PMid:35460893
64. Deng Y, Qiao L, Du M, Qu C, Wan L, Li J, Huang L. Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes & diseases. 2022 Jan 1;9(1):62-79. https://doi.org/10.1016/j.gendis.2021.02.009 PMid:35005108 PMCid:PMC8720701
65. Blasiak J, Pawlowska E, Ciupińska J, Derwich M, Szczepanska J, Kaarniranta K. A new generation of gene therapies as the future of wet AMD treatment. International Journal of Molecular Sciences. 2024 Feb 17;25(4):2386. https://doi.org/10.3390/ijms25042386 PMid:38397064 PMCid:PMC10888617
66. Wolf AT, Harris A, Oddone F, Siesky B, Verticchio Vercellin A, Ciulla TA. Disease progression pathways of wet AMD: opportunities for new target discovery. Expert opinion on therapeutic targets. 2022 Jan 2;26(1):5-12. https://doi.org/10.1080/14728222.2022.2030706 PMid:35060431 PMCid:PMC8915198
67. Papaioannou C. Advancements in the treatment of age-related macular degeneration: A comprehensive review. Postgraduate Medical Journal. 2024 Jul;100(1185):445-50. https://doi.org/10.1093/postmj/qgae016 PMid:38330506
68. Miller JW, D'Anieri LL, Husain D, Miller JB, Vavvas DG. Age-related macular degeneration (AMD): a view to the future. Journal of Clinical Medicine. 2021 Mar 8;10(5):1124. https://doi.org/10.3390/jcm10051124 PMid:33800285 PMCid:PMC7962647
69. Guymer R, Wu Z. Age‐related macular degeneration (AMD): More than meets the eye. The role of multimodal imaging in today's management of AMD-A review. Clinical & Experimental Ophthalmology. 2020 Sep;48(7):983-95. https://doi.org/10.1111/ceo.13837 PMid:32741052
70. Singh M, Negi R, Alka, Vinayagam R, Kang SG, Shukla P. Age-related macular degeneration (AMD): pathophysiology, drug targeting approaches, and recent developments in nanotherapeutics. Medicina. 2024 Oct 8;60(10):1647. https://doi.org/10.3390/medicina60101647 PMid:39459435 PMCid:PMC11509623
Published
Abstract Display: 680 
PDF Downloads: 801 PDF Downloads: 95 How to Cite
Issue
Section
Copyright (c) 2025 Rakhi Mishra , Avishikta Ray Das , Archana Sahu , Ankit Gupta
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.